ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. announced today that it has successfully tested a prototype of its wireless heart monitor utilizing Bluetooth(R) technology delivered by Cambridge Silicon Radio’s (CSR) BlueCore3. The integration of this Bluetooth component signifies the final step in the development of Telzuit’s flagship 12-lead wireless heart monitor, readying the product for its initial production run and positioning it for formal launch in 2006. The completion of this prototype also clears the way for final development and implementation of the company’s other leading mobile medical devices, including: an FDA-approved 12-lead wireless cardiac event monitor; a home sleep apnea test; and a long-term care patient solution incorporating the company’s core wireless technology.
Warren Stowell, CEO of Telzuit, commented, “The successful Bluetooth prototype test represents the final technological step in the development of our signature wireless Holter monitor. With this objective complete we now commence the initial production cycle of our mobile heart monitoring devices, and remain well-positioned for the product’s forthcoming market roll-out. The successful Bluetooth integration is also an important step forward in the life cycle of our other revolutionary mobile medical devices, validating the effectiveness of core wireless technology and driving our diversified product pipeline a step closer to fruition.”
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The company is in the final stages of launching its first product, an FDA-approved wireless heart monitor. The product is a full 12-lead, completely wireless Holter monitor, which is new to the marketplace. In conjunction with its strategic partners, Telzuit is also building its own dedicated intranet platform to handle several of the products it will be releasing, including the wireless Holter monitor. Telzuit is based in Orlando, Florida. For more information on Telzuit, its business model and its products, please visit the company’s Web site: http://www.telzuit.com.
Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contact: For Telzuit Medical Technologies, Inc. James Tolan Co-Founder, Telzuit Medical Technologies, Inc +1-407-354-1222 Brainerd Communicators, Inc. Jennifer Gery (media) Todd St.Onge (investors) +1-212-986-6667
Telzuit Medical Technologies, Inc.
CONTACT: James Tolan, Co-Founder of Telzuit Medical Technologies, Inc.,+1-407-354-1222; or Jennifer Gery (media), or Todd St.Onge (investors),both of Brainerd Communicators, Inc., +1-212-986-6667
Web site: http://www.telzuit.com/